Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,267 across all filing types
Latest filing 2021-03-17 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the loss of share certificates and the request for issuance of duplicate share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. It is an announcement related to shareholding records and regulatory compliance rather than a financial report or management information. The content fits best under a regulatory announcement category related to shareholding and compliance disclosures. Given the nature of the document, it does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a Director's Dealing or Major Shareholding Notification since it concerns lost share certificates and duplicate issuance. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-03-17 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) informing about AstraZeneca Pharma India Limited receiving Import and Market Permission (Form CT-20) from the Drugs Controller General of India for a new drug indication. It is an announcement of a regulatory approval related to product launch, not a financial report, earnings release, or management discussion. The document is short (1766 characters) and serves as an official regulatory announcement to the exchanges. It does not contain financial data, management changes, or voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-10 English
This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) informing about AstraZeneca Pharma India Limited receiving Import and Market Permission (Form CT-20) from the Drugs Controller General of India for a new drug indication. The content is an announcement of a regulatory approval related to product launch, not a financial report, earnings release, or management discussion. It does not contain financial data, management changes, voting results, or legal proceedings. It is a regulatory announcement informing the exchanges and public about a material event related to the company's product approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-10 English
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates and the request for issuance of duplicate certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. It is an announcement related to share certificates, which fits the category of Regulatory Filings (RNS) as it is a compliance notification rather than a financial report or capital change announcement. The document length is short and it is not a report or announcement of a report publication.
2021-03-06 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates and the request for issuance of duplicate certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. The document is an announcement related to share certificates, which fits the category of Regulatory Filings (RNS) as it is a compliance disclosure rather than a financial report or shareholder meeting material. The document length is short and it is not a report itself but a notification.
2021-03-06 English
Loss of Share Certificates
Regulatory Filings Classification · 90% confidence The document text is mostly unreadable or in an unrecognized script, with many characters replaced by placeholders or corrupted symbols. There are no clear indications of report titles, fiscal periods, regulatory bodies, or specific financial data. The document length is only 1921 characters, which is quite short and suggests it might be an announcement or a brief notice rather than a full report. Given the lack of recognizable content and the short length, it is most appropriate to classify this as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other specific categories.
2021-02-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.